2019 novel‐coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications

Chronic Diseases and Translational Medicine - Tập 6 - Trang 246-250 - 2020
Luigi Cappannoli1, Roberto Scacciavillani1, Giulia Iannaccone1, Gianluca Anastasia1, Federico Di Giusto1, Valentina Loria1, Nadia Aspromonte1
1Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy

Tóm tắt

AbstractFrom December 31st, 2019, a novel highly pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has spread worldwide, reaching at present the dimension of a pandemic. In addition to damaging the lungs, SARS‐CoV‐2 may also damage the heart and this is corroborated by the evidence that cardiovascular comorbidities are associated with a higher mortality and poor clinical outcomes in patient infected by the virus. During the infection myocardial injury, myocarditis and arrhythmias have also been reported, but the pathophysiological mechanisms of these complications are yet to be understood. Great attention is also being posed on the potential beneficial/harmful role of angiotensin converting enzyme (ACE) inhibitors, as far as the virus binds to ACE2 to infect cells, but evidences lack. Furthermore, SARS‐CoV‐2 can also affect the aspect of acute coronary syndromes, not only because these two distinct pathological entities share pathogenic aspects (such as the systemic inflammatory state and cytokine release), but also and above all for the consequences that the need to contain the infection has on the management of cardiological urgencies. The aim of this review was therefore to summarize the relationship between the virus and the cardiovascular system.

Tài liệu tham khảo

10.1016/S0140-6736(20)30211-7 10.1056/NEJMoa2002032 10.1007/s00392-020-01626-9 10.1001/jama.2020.2648 Onder G., 2020, Case‐fatality rate and characteristics of patients dying in relation to COVID‐19 in Italy, JAMA, 323, 1775 10.1001/jamainternmed.2020.0994 10.1001/jama.2020.1585 10.1002/path.1440 10.5144/0256-4947.2016.78 Chen C., 2020, Analysis of myocardial injury in patients with COVID‐19 and association between concomitant cardiovascular diseases and severity of COVID‐19 (in Chinese), Chin J Cardiol, 48, E008 10.1093/eurheartj/ehaa231 10.1016/S0140-6736(20)30566-3 10.1016/S0140-6736(20)30183-5 10.1007/s00059-020-04909-z 10.1001/jamacardio.2020.0950 10.1001/jamacardio.2020.1017 10.1016/j.pcad.2020.03.001 10.1001/jamacardio.2020.1096 10.1093/eurheartj/ehaa190 10.1111/j.1365-2362.2009.02153.x 10.1161/01.RES.87.5.e1 10.1016/j.cell.2020.02.052 10.1161/CIRCULATIONAHA.104.510461 10.1093/eurheartj/ehaa235 10.1186/s13054-017-1823-x Peng Y.D., 2020, Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019‐nCoV (in Chinese), Chin J Cardiol, 48, E004 2020, Position Statement of the ESC Council on Hypertension on ACE‐Inhibitors and Angiotensin Receptor Blockers 2020, HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID‐19 10.1016/j.diabres.2020.108142 10.1016/S0140-6736(03)13412-5 10.1038/s41418-020-0530-3 10.1016/j.dsx.2020.03.013 10.1111/jth.14768 COVID‐19 Clinical Guidance For the Cardiovascular Care Team.Diagnostic and Interventional Cardiology.https://www.dicardiology.com/article/acc‐covid‐19‐clinical‐guidance‐cardiovascular‐care‐team2020Accessed March 9 2020 Zhu Z.W., 2020, Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics (in Chinese), Chin J Cardiol, 48, E007 10.1161/CIRCULATIONAHA.120.047122
Thông tin
Thông tin xuất bản

Chronic Diseases and Translational Medicine

Tập 6

246-250

Thông tin tác giả